The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses

The interval between courses of chemotherapy have classically been kept to a minimum in order to maximize dose intensity. Certain clinical observation s suggest that longer intervals, particularly in the high-dose setting, may be more effective. This is based in part on the evidence that resistance i s reversible over time and that the interval should be sufficient to allow for such a reversal. Clinical evidence for such reversibility include the f ollowing. In metastatic breast cancer, double or double high-dose stem cell rescue (HD-SCR) studies involving a minimal interval, have not, at least a s yet, been shown to be superior to single HD-SCR, In Hodgkin's disease, re sponse after relapse correlates directly with duration of time to relapse. Tn a comparative study of metastatic breast cancer, early HD-SCR preceded b y daunorubicin induction was inferior to delayed HD-SCR, The latter was not preceded by induction chemotherapy, In a comparative study of childhood AL L, patients randomized to delayed (4 month interval) intensification had a significantly; superior survival as compared to patients randomized to imme diate (1 month interval) intensification. Taken together, these clinical ob servations indicate that resistance is reversible and that optimization of the interval must take this into account. Cytokinetic modeling of those cli nical studies also found that delayed HD-SCR could result in a superior eff ect. Cytokinetic models of minimal residual tumor which were also examined included the Skipper exponential model, the Norton-Simon model which emphas izes the Gompertzian effect, the clonal evolution model, and the Retsky-Dem isheli model which derives from a bimodal relapse pattern above, Biological and clinical data have resulted in a clinical protocol in the CALGB wherei n patients with metastatic breast cancer are randomly allocated to (1) a si ngle HD-SCR arm; (2) a double HD-SCR with a 5-week interval; and (3) a doub le HD-SCR arm with a 16 week interval.